Serum HER2 Level Predicts Therapeutic Efficacy and Prognosis in Advanced Breast Cancer Patients [Letter]

Febie Irsandy Syahruddin1 Department of Radiology, Faculty of Medicine, Universitas Muslim Indonesia, Makassar, IndonesiaCorrespondence[email protected]

Prihantono2 Department of Surgery, Faculty of Medicine, Hasanuddin University, Makassar, Indonesia

Mirna Muis3 Department of Radiology, Faculty of Medicine, Hasanuddin University, Makassar, Indonesia

References

Wang S, Chen Y, Li W, Zhao W, Shi Y, Tong Z. Serum HER2 level predicts therapeutic efficacy and prognosis in advanced breast cancer patients. Breast Cancer Targets Ther. 2024;16:163–179. doi:10.2147/BCTT.S449510</INTDOI>
PubMedGoogle Scholar
Schlam I, Tolaney SM, Tarantino P. How I treat HER2-low advanced breast cancer. Breast. 2023;67:116–123. doi:10.1016/j.breast.2023.01.005
PubMed Web of Science ®Google Scholar
Nobbe K, Erices-Leclercq M, Foerster F, et al. HER2 low expression in primary male breast cancer. Breast Cancer Targets Ther. 2024;16:141–148. doi:10.2147/BCTT.S450682
PubMed Web of Science ®Google Scholar
Alataki A, Dowsett M. Human epidermal growth factor receptor-2 and endocrine resistance in hormone-dependent breast cancer. Endocr Relat Cancer. 2022;29(8):R105–R122. doi:10.1530/ERC-21-0293
PubMed Web of Science ®Google Scholar
Sharaf B, Abu-Fares H, Tamimi F, et al. Differences in treatment outcomes between patients with HER2-low versus HER2-zero, hormone receptor-positive advanced-stage breast cancer treated with ribociclib. Breast Cancer Targets Ther. 2023;15:541–548. doi:10.2147/BCTT.S415432
PubMed Web of Science ®Google Scholar